Inozyme Pharma CEO Douglas Treco receives $5.3M in 2023
Inozyme Pharma reports 2023 executive compensation
By ExecPay News
Published: April 26, 2024
Inozyme Pharma reported fiscal year 2023 executive compensation information on April 26, 2024.
In 2023, four executives at Inozyme Pharma received on average a compensation package of $2.4M, a 64% increase compared to previous year.
Average pay of disclosed executives at Inozyme Pharma
Douglas Treco, Chief Executive Officer, received $5.3M in total. 78% of Treco's compensation, or $4.1M, was in option awards. Treco also received $7.5K in bonus, $200K in non-equity incentive plan, $375K in salary, $573K in stock awards, as well as $9.4K in other compensation.
Axel Bolte, Chief Executive Officer, received a compensation package of $1.8M, which decreased by 19% compared to previous year. 49% of the compensation package, or $883K, was in other compensation.
Matthew Winton, Chief Operating Officer, earned $1.5M in 2023.
Sanjay S. Subramanian, Chief Financial Officer, received $1M in 2023, which decreases by 17% compared to 2022.
Related executives
You may also like
Source: SEC filing on April 26, 2024.